On Wednesday, the US Patent and Trademark Workplace (USPTO) issued a Discover of Allowance for a brand new patent associated to Anixa Biosciences, Inc.’s ANIX breast most cancers vaccine expertise.
Cleveland Clinic has solely licensed the patent and others associated to this expertise to Anixa Biosciences. The patent will develop the scope of immunogenic compositions utilized in Anixa’s breast most cancers vaccine.
Additionally Learn: EXCLUSIVE: Anixa Biosciences Inks Letter of Intent with Austria-Primarily based VERDI Options To Develop AI-Guided Customized Most cancers Vaccines
This newly allowed patent covers strategies of immunizing sufferers towards breast most cancers by administering an immunogenic composition containing the human α-lactalbumin protein, a protein usually present in breast tissue throughout lactation but additionally expressed in sure breast cancers.
Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, said, “This patent strengthens our mental property portfolio and highlights the novelty of our breast most cancers vaccine. Our mental property portfolio consists of a number of issued and pending patents within the U.S. and worldwide jurisdictions.”
In March, the USPTO issued a Discover of Allowance for a key patent utility protecting Anixa Biosciences ovarian most cancers vaccine expertise.
The patent consists of broad claims associated to strategies of eliciting an immune response concentrating on the Anti-Mullerian Hormone Receptor, Kind II (AMHR2), a goal for ovarian most cancers prevention and remedy.
Anixa’s ovarian most cancers vaccine is being developed in collaboration with Cleveland Clinic and the Nationwide Most cancers Institute.
The allowed claims embrace strategies of administering an immunogenic composition comprising a nucleic acid encoding the AMHR2 polypeptide, particularly the extracellular area of human AMHR2, to elicit an AMHR2-specific immune response.
Value Motion: ANIX inventory closed at $2.38 on Tuesday.
Learn Subsequent:
Market Information and Knowledge delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
